CSL Limited Sponsored ADR (OTCMKTS:CSLLY – Get Free Report) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $17.7765 and last traded at $18.1350, with a volume of 2722 shares. The stock had previously closed at $21.81.
Wall Street Analysts Forecast Growth
Separately, Royal Bank Of Canada downgraded CSL from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, CSL presently has a consensus rating of “Moderate Buy”.
Check Out Our Latest Analysis on CSL
CSL Price Performance
CSL Company Profile
CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.
The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.
Read More
- Five stocks we like better than CSL
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
